Skip to main content
Year archive

SYNTARA LIMITED — 2020 filings

All 65 regulatory filings released by SYNTARA LIMITED (SNT) in 2020, sourced directly from the official regulator.

65 Filings
2020 Period
2020 filings (65)
Filing Released Lang
Pharmaxis Receives US$7m milestone from Chiesi 1 pa
Capital/Financing Update
2020-12-28 English
Appendix 2A - exercise of employee options 15 pages 198.4KB
Share Issue/Capital Change
2020-12-16 English
Pharmaxis to Present at Proactive CEO Investor Session 2 pages 100.4KB
Regulatory Filings
2020-11-09 English
Change in substantial holding 4 pages 130.6KB
Major Shareholding Notification
2020-11-05 English
Chairman's Address to Shareholders 2 pages 153.3KB
AGM Information
2020-11-03 English
CEO Presentation to AGM 15 pages 1.7MB
AGM Information
2020-11-03 English
Results of Meeting 2 pages 186.6KB
Declaration of Voting Results & Voting Rights Announcements
2020-11-03 English
Appendix 3G - Employee Options 13 pages 178.2KB
Share Issue/Capital Change
2020-11-03 English
Change of Director's Interest Notice 2 pages 145.2KB
Director's Dealing
2020-11-03 English
Ceasing to be a substantial holder from Arix Bioscience 3 pages 241.1KB
Major Shareholding Notification
2020-11-02 English
FDA Approves Bronchitol for US Market 3 pages 132.9KB
Capital/Financing Update
2020-11-01 English
Pharmaxis Prioritises Clinical Program on Myelofibrosis 3 pages 135.5KB
Capital/Financing Update
2020-11-01 English
Investor Teleconference 2 pages 111.0KB
Call Transcript
2020-11-01 English
Investor Presentation 27 pages 3.2MB
Investor Presentation
2020-11-01 English
MEDIA RELEASE BRONCHITOL FDA and MF Trial 3 pages 124.2KB
Capital/Financing Update
2020-11-01 English
September Quarter 2020 Activity Report 9 pages 366.5KB
Interim / Quarterly Report
2020-10-29 English
Appendix 4C - quarterly 5 pages 187.3KB
Interim / Quarterly Report
2020-10-29 English
Change in substantial holding from Arix Bioscience 3 pages 155.3KB
Major Shareholding Notification
2020-10-22 English
Change in substantial holding 4 pages 199.2KB
Regulatory Filings
2020-10-19 English
Pharmaxis Receives $5m R&D Tax Incentive 2 pages 104.4KB
Capital/Financing Update
2020-10-13 English
Annual Report to shareholders 68 pages 928.0KB
Annual Report
2020-10-01 English
Notice of Annual General Meeting/Proxy Form 19 pages 1.5MB
AGM Information
2020-10-01 English
Appendix 4G 14 pages 187.3KB
Governance Information
2020-10-01 English
Corporate Governance Statement 19 pages 199.4KB
Governance Information
2020-10-01 English
Appendix 2A - exercise of employee options 15 pages 198.4KB
Regulatory Filings
2020-09-30 English
Appendix 2A - Exercise of Employee Options 15 pages 198.5KB
Share Issue/Capital Change
2020-09-23 English
Appendix 2A - Exercise of Employee Options 16 pages 199.5KB
Capital/Financing Update
2020-09-17 English
Date of Virtual AGM and Closing Date for Director Nomination 1
AGM Information
2020-09-15 English
Boehringer Ingelheim discontinues development of BI 1467335 2 pages 697.3KB
Regulatory Filings
2020-09-06 English
Pharmaxis Awarded $1M Australian Government Grant 2 pages 128.1KB
Capital/Financing Update
2020-09-02 English
Appendix 2A - Employee Option Exercise 16 pages 199.5KB
Capital/Financing Update
2020-08-24 English
Appendix 2A - 2020 Employee Share Plan Grant 15 pages 203.0KB
Regulatory Filings
2020-08-23 English
FDA Gives Green Light to Start Myelofibrosis Phase 2 Study 2 pages 94.9KB
Regulatory Filings
2020-08-18 English
Resignation of Non Executive Director Edward Rayner 2 pages 103.1KB
Board/Management Information
2020-08-13 English
Final Director's Interest Notice 2 pages 115.1KB
Director's Dealing
2020-08-13 English
Appendix 2A - Exercise of employee options 16 pages 200.1KB
Capital/Financing Update
2020-08-13 English
Preliminary Final Report 64 pages 956.9KB
Annual Report
2020-08-12 English
Lapse of 2019 Performance Rights and Expiry of Options 1
Regulatory Filings
2020-08-12 English
Change of Director's Interest Notice - G Phillips 2 pages 148.4KB
Director's Dealing
2020-08-12 English
Appendix 3G - 2020 Grant of Performance Rights 13 pages 178.3KB
Share Issue/Capital Change
2020-08-12 English
Proposed Issue of Securities to Chief Executive Officer 2 pages 164.8KB
Share Issue/Capital Change
2020-08-12 English
US$7 million Bronchitol Launch Milestone Brought Forward 2 pages 104.8KB
Capital/Financing Update
2020-08-04 English
Appendix 4C - quarterly 5 pages 178.7KB
Interim / Quarterly Report
2020-07-30 English
Fourth Quarter Activity Report 10 pages 387.4KB
Interim / Quarterly Report
2020-07-30 English
Pharmaxis Submits IND Application for Myelofibrosis 2 pages 94.4KB
Regulatory Filings
2020-07-22 English
FDA Grants Orphan Drug Status for PXS Anti Fibrotic Drug 2 pages 143.6KB
Regulatory Filings
2020-07-13 English
PHARMAXIS TO PRESENT AT MONSOON COMMUNICATIONS WEBINAR 1
Investor Presentation
2020-06-01 English
Appendix 2A - Exercise of Employee Options 16 pages 219.8KB
Regulatory Filings
2020-05-17 English
Appendix 2A - Exercise of Employee Options Number 2 16 pages 219.8KB
Capital/Financing Update
2020-05-17 English
Bronchitol NDA Resubmission - FDA Decision Date 1 November 2 pages 519.8KB
Regulatory Filings
2020-05-12 English
Chiesi Files Resubmission for Bronchitol with FDA 2 pages 110.2KB
Regulatory Filings
2020-05-04 English
Pharmaxis Appoints Dr Neil Graham as Director 2 pages 106.4KB
Board/Management Information
2020-05-03 English
Initial Director's Interest Notice 2 pages 136.2KB
Director's Dealing
2020-05-03 English
Investor Presentation 19 pages 952.8KB
Investor Presentation
2020-04-30 English
Pharmaxis Quarterly Shareholder Update - March 2020 9 pages 390.9KB
Interim / Quarterly Report
2020-04-29 English
Appendix 4C - quarterly 5 pages 91.6KB
Interim / Quarterly Report
2020-04-29 English
Pharmaxis CEO to Present at Virtual Health Conference 1
Investor Presentation
2020-04-29 English
PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020 3 pages 149.6KB
Regulatory Filings
2020-04-27 English
Appendix 2A - Exercise of Employee Options 16 pages 116.4KB
Capital/Financing Update
2020-04-05 English
Appendix 2A - Exercise of Employee Options 16 pages 102.7KB
Capital/Financing Update
2020-03-11 English
Appendix 2A 16 pages 102.8KB
Regulatory Filings
2020-02-12 English
Half Yearly Report and Accounts 23 pages 256.7KB
Interim / Quarterly Report
2020-02-12 English
Appendix 3G - Exercise of Employee Options 12 pages 80.9KB
Share Issue/Capital Change
2020-02-11 English
Quarterly Shareholder Update - December 2019 9 pages 376.2KB
Interim / Quarterly Report
2020-01-30 English
Appendix 4C - quarterly 5 pages 125.6KB
Interim / Quarterly Report
2020-01-30 English